Tom Brutnell

Company: Gateway Biotechnology Inc.

Job title: Chief Operating Officer & Vice President

Seminars:

Exploring Novel Small Molecule & Gene Therapeutic Approaches for Tinnitus Indications for Improved Patient Care 12:00 pm

Development of an operant behavioral mouse and gerbil model for Tinnitus drug discovery • GW-TT2 – Repurposing small molecule targeting Meniere’s disease-associated Tinnitus, delivered intra-nasally Development of a novel two-component gene therapy approach (GW-TT5) for the treatment of severe debilitating Tinnitus Incorporating biomarkers and improved diagnostics in preclinical and clinical designs for more predictable outcomesRead more

day: Conference Day 1

Panel Discussion & Live Audience Q&A: Gene Therapy Lessons for Rare Hearing Loss 1:30 pm

2024 starts with a bang, thanks to back-to-back positive results in gene therapies for paediatric rare hearing disorders. Join this expert panel discussion to hear from gene therapy experts and leverage lessons from other diseases areas when developing and progressing gene therapy for rare hearing loss. Discussing the expansion of the gene therapy field into…Read more

day: Conference Day 1